Vale Biolabs raises €164K to grow brain tissue in the lab and test drugs with AI
Swiss biotech startup Vale Biolabs has raised €164,000 from Venture Kick to build a platform that skips animal testing. Instead, the team grows lab-made human brain tissue, pairs it with AI, and tests drug responses in a system that behaves like a real human brain.
Editor, Lazyfounder
30 SEC SUMMARY
- Swiss biotech startup Vale Biolabs has secured €164,000 from Venture Kick to replace animal testing in brain disease research.
- The team grows miniaturized human brain tissue in the lab and pairs it with AI to test drug responses more accurately.
- Preclinical studies for Alzheimer’s, Parkinson’s and rare disorders could fail less often because the models mimic human biology.
- The funding will expand the startup’s automated platform and train its AI on larger datasets.
TABLE OF CONTENTS
€164K to replace animal tests in brain research
Swiss funding initiative Venture Kick has awarded Vale Biolabs €164,000 (CHF 150,000) to build a platform that studies brain diseases without relying on animal testing. The startup grows human brain tissue in the lab and uses AI to predict how drugs will behave in patients.
Four founders merge brain tissue, robots and AI
Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano and Theodoulos Rodosthenous launched Vale Biolabs to merge organoid neurobiology, automation and data science. Incaviglia and Damilou specialize in growing miniature brain models that mimic human tissue. Medina Cano and Rodosthenous add expertise in robotics and AI, allowing the team to monitor how brain organoids respond to experimental drugs.
Why nine in ten brain drugs fail in humans
Nearly nine out of ten Alzheimer’s drugs that pass animal tests fail in human trials. Parkinson’s compounds face similar odds. Vale Biolabs argues that these failures stem from fundamental biological differences between species. Its lab-grown brain organoids, the startup says, can show how a human brain would actually react—before a drug ever reaches trial volunteers.
AI flags winners and losers before human trials
Vale Biolabs’ platform tracks structural, electrical and molecular changes in brain organoids before and after drug exposure. The data feeds predictive AI models that flag which compounds are likely to work and which are likely to fail. The startup is targeting Alzheimer’s, Parkinson’s and rare pediatric brain disorders that currently lack reliable preclinical models.
Next: robots, data and pharma partnerships
The €164,000 grant will help the team expand its robotic testing platform, grow more diverse brain organoids, and compile datasets that train the AI. Vale Biolabs also plans to deepen collaborations with pharmaceutical companies and academic labs to validate its models in real-world drug programs.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
By skipping animal models, Vale Biolabs could cut years and millions from drug development timelines—especially for diseases where animal tests have no human equivalent.
Key takeaways
- Lab-grown brain tissue combined with AI could reduce clinical-trial failures for Alzheimer’s and Parkinson’s drugs.
- Automating organoid tests may lower costs and speed up early-stage drug screening.
- Investors are backing niche platforms that promise to bridge the gap between lab research and human trials.
Related on Lazyfounder
Sources
- Tech.eu · 2026-11-09
Vale Biolabs receives €164K from Venture Kick to advance brain disease research
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.
